Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Ann Hematol ; 96(8): 1323-1330, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28536895

ABSTRACT

Guidelines recommend autologous stem cell transplantation (ASCT) consolidation in first complete or partial response after regimens including rituximab (R) and high-dose AraC (HDAC), but its use beyond that response is questioned. We present a retrospective analysis of 268 patients with MCL who received ASCT. With a median follow-up for survival patients of 54 months, progression-free survival and overall survival for the whole series were 38 and 74 months, respectively, and for patients transplanted in first CR 49 and 97 months, respectively. Patients without CR before transplant were analyzed separately, those who achieved CR after transplantation had better PFS (48 vs 0.03 months, p < 0.001) and OS (92 vs 16 months, p < 0.001) than the remaining. In univariate analysis, first CR at transplant (p = 0.01) and prior rituximab (p = 0.02) were the variables associated with PFS. For OS, the same variables resulted significant (p = 0.03 and p < 0.001, respectively). In multivariate analysis, only the status at transplant (first CR) remained significant. This retrospective study concludes that ASCT consolidation in first CR induces high survival rates. In other stages of disease, the need of ASCT as consolidation may be questioned.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematopoietic Stem Cell Transplantation/methods , Lymphoma, Mantle-Cell/therapy , Adult , Aged , Cytarabine/administration & dosage , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Outcome Assessment, Health Care/methods , Outcome Assessment, Health Care/statistics & numerical data , Proportional Hazards Models , Remission Induction , Retrospective Studies , Rituximab/administration & dosage , Transplantation Conditioning , Transplantation, Autologous , Young Adult
2.
Leuk Res ; 39(3): 296-306, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25601157

ABSTRACT

Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML) patients and to develop a clinical prediction model to identify which patients may benefit more from the drug. One hundred and ten untreated unfit AML patients received front-line azacitidine therapy in Spain, and response and survival were evaluated in them following European LeukemiaNet (ELN) guidelines. A clinical prediction rule was obtained from this population that was validated and refined in 261 patients treated in France, Austria and Italy. ELN response was achieved in 21.0% of the 371 patients (CI95% 17.0-25.5) and did not depend on bone marrow blast cell percentage. Median overall survival was 9.6 months (CI95% 8.5-10.8) and 40.6% of the patients were alive at 1 year (CI95% 35.5-45.7). European ALMA score (E-ALMA), based on performance status, white blood cell counts at azacitidine onset and cytogenetics, discriminated three risk groups with different survival and response rates. Azacitidine seems a reasonable therapeutic option for most unfit AML patients, i.e. those displaying a favorable or intermediate E-ALMA score.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Azacitidine/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Leukemia, Myeloid, Acute/mortality , Male , Middle Aged , Remission Induction , Retrospective Studies , Survival Rate , Treatment Outcome , Validation Studies as Topic
3.
Med Mycol ; 51(2): 150-4, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22712457

ABSTRACT

Caspofungin is an echinocandin with proven efficacy in invasive candidiasis (IC) and invasive aspergillosis (IA). This multicenter, prospective, non-comparative, observational ProCAS study was aimed to assess the effectiveness and safety of caspofungin in adult hematological patients with IC or IA under everyday clinical conditions. Favorable outcomes included complete and partial responses on the last day of caspofungin therapy. Safety was assessed up to 14 days post-caspofungin. A total of 115 patients (69 male) with a median age of 52 years (range, 23-78 years) were analyzed. Underlying disease was acute myeloid leukemia in 45 patients (39%), and 21 (18%) were allogeneic stem cell transplant recipients. Thirty-four (29.5%) patients had a diagnosis of IA and 26 (22.6%) had IC (candidemia). The median duration of caspofungin therapy was 14 days (range, 1-100). The overall favorable response rate was 77% (20/26) for patients with IC (69% first-line) and 79% (27/34) for those with IA. Antifungal therapy with caspofungin was generally well tolerated, only two (1.7%) patients having a non-serious drug-related adverse reaction. These results suggest that caspofungin, either alone or in combination, should be considered an effective and safe option for the treatment of invasive mycoses in patients with severe hematological disorders.


Subject(s)
Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Candidemia/drug therapy , Candidiasis, Invasive/drug therapy , Echinocandins/therapeutic use , Adult , Aged , Aspergillosis/complications , Aspergillosis/microbiology , Aspergillus/drug effects , Aspergillus/isolation & purification , Candida/drug effects , Candida/isolation & purification , Candidemia/complications , Candidemia/microbiology , Candidiasis, Invasive/complications , Candidiasis, Invasive/microbiology , Caspofungin , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Leukemia, Myeloid, Acute/complications , Lipopeptides , Male , Middle Aged , Prospective Studies , Safety , Transplantation, Homologous , Treatment Outcome , Young Adult
4.
Actas Dermosifiliogr ; 97(6): 385-90, 2006.
Article in Spanish | MEDLINE | ID: mdl-16956518

ABSTRACT

Human herpes virus 8 (HHV8) was discovered in 1994 in the biopsy of a Kaposi's sarcoma in a patient with AIDS. Since then it has been identified in all variants of Kaposi's sarcoma and in another two rare disorders: multicentric Castleman's disease and primary body-cavity based lymphomas. The case discusses a 68 year old, HIV-negative male patient, presenting Kaposi's sarcoma for one year and being monitored by dermatology, who presented for weakness, anorexia and fever. On examination, he was found to have adenitis of the lymph nodes in his neck, underarm and groin. A biopsy on one of the swellings led to findings characteristic of multicentric plasma cell variant Castleman's disease. Blood tests for HHV8 and HIV were carried out, resulting positive and negative respectively (IgG anti-HHV8 positive, title 1/640, indirect immunofluorescence). PCR amplification showed HHV8 in peripheral blood. Patient received 8 cycles of CHOP and rituximab, leading to complete disappearance of the adenitis and general symptoms, with no worsening of his Kaposi's sarcoma. Patient remained in complete remission for 10 months after treatment. This paper discusses the case of a HIV-, HHV8+ patient, diagnosed with classic Kaposi's sarcoma, who developed multicentric plasma cell variant Castleman's disease. The coincidence of two or more HHV8-related illnesses in a HIV-negative patient has rarely been described in medical literature. Treatment with rituximab combined with CHOP chemotherapy was effective in this case, and no worsening of the patient's KS was observed.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Castleman Disease/complications , HIV Seronegativity , Herpesvirus 8, Human , Sarcoma, Kaposi/complications , Sarcoma, Kaposi/drug therapy , Skin Neoplasms/complications , Skin Neoplasms/drug therapy , Aged , Antibodies, Monoclonal, Murine-Derived , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Humans , Male , Prednisone/therapeutic use , Rituximab , Vincristine/therapeutic use
5.
Actas dermo-sifiliogr. (Ed. impr.) ; 97(6): 385-390, jul. 2006. ilus, tab
Article in Es | IBECS | ID: ibc-046624

ABSTRACT

El virus herpes humano tipo 8 (VHH-8) se descubrió en 1994 a partir de la biopsia de un sarcoma de Kaposi en un paciente con sida. Desde entonces se ha identificado en todas las variantes de sarcoma de Kaposi y en otros dos raros procesos: la enfermedad de Castleman multicéntrica y el linfoma primario de cavidades. Se presenta el caso de un paciente varón de 68 años de edad VIH-negativo con sarcoma de Kaposi de un año de evolución en seguimiento por Dermatología que consultó por astenia, anorexia y fiebre. A la exploración se detectaron múltiples adenopatías laterocervicales, axilares e inguinales. En la biopsia de una de dichas adenopatías se apreciaron hallazgos característicos de la variante de células plasmáticas de la enfermedad de Castleman. Se realizaron serologías para el VHH-8 y el VIH que resultaron positiva y negativa respectivamente (IgG anti-VHH-8 positivo, título 1/640, inmunofluorescencia indirecta). Mediante reacción en cadena de la polimerasa se amplificó VHH-8 en sangre periférica. El paciente recibió tratamiento con 8 ciclos de CHOP y rituximab con una completa resolución de las adenopatías y la sintomatología general sin observarse empeoramiento de su sarcoma de Kaposi. El paciente permanece en remisión completa 10 meses después de finalizado el tratamiento. Se presenta el caso de un paciente VIH-negativo y VHH-8-positivo, diagnosticado de sarcoma de Kaposi clásico que desarrolló una enfermedad de Castleman multicéntrica variante de células plasmáticas. La coincidencia de dos o más enfermedades relacionadas con el VHH-8 en un paciente VIH-negativo es un hecho descrito raramente en la literatura. El tratamiento con rituximab combinado con quimioterapia tipo CHOP ha demostrado ser eficaz en este caso sin que haya podido observarse un agravamiento de su SK


Human herpes virus 8 (HHV8) was discovered in 1994 in the biopsy of a Kaposi's sarcoma in a patient with AIDS. Since then it has been identified in all variants of Kaposi's sarcoma and in another two rare disorders: multicentric Castleman's disease and primary body-cavity based lymphomas. The case discusses a 68 year old, HIV-negative male patient, presenting Kaposi's sarcoma for one year and being monitored by dermatology, who presented for weakness, anorexia and fever. On examination, he was found to have adenitis of the lymph nodes in his neck, underarm and groin. A biopsy on one of the swellings led to findings characteristic of multicentric plasma cell variant Castleman's disease. Blood tests for HHV8 and HIV were carried out, resulting positive and negative respectively (IgG anti-HHV8 positive, title 1/640, indirect immunofluorescence). PCR amplification showed HHV8 in peripheral blood. Patient received 8 cycles of CHOP and rituximab, leading to complete disappearance of the adenitis and general symptoms, with no worsening of his Kaposi's sarcoma. Patient remained in complete remission for 10 months after treatment. This paper discusses the case of a HIV­, HHV8+ patient, diagnosed with classic Kaposi's sarcoma, who developed multicentric plasma cell variant Castleman's disease. The coincidence of two or more HHV8-related illnesses in a HIV-negative patient has rarely been described in medical literature. Treatment with rituximab combined with CHOP chemotherapy was effective in this case, and no worsening of the patient's KS was observed


Subject(s)
Male , Aged , Humans , Herpesvirus 8, Human/pathogenicity , Herpesviridae Infections/diagnosis , Sarcoma, Kaposi/complications , Castleman Disease/complications , Herpesviridae Infections/drug therapy , Cyclophosphamide/therapeutic use , Vincristine/therapeutic use , Prednisone/therapeutic use
6.
Arch Bronconeumol ; 40(6): 287-9, 2004 Jun.
Article in Spanish | MEDLINE | ID: mdl-15161597

ABSTRACT

The most common cause of Pancoast syndrome is bronchogenic carcinoma. Other less common causes are solid tumor metastases, other chest tumors, infections, and hematologic neoplasms. Pancoast syndrome due to lymphoma is very rare, and cases described in the literature are essentially associated with non-Hodgkin lymphomas. In a review of the literature we found a single case of Pancoast syndrome secondary to a Hodgkin lymphoma; however, the syndrome manifested during recurrence of disease in that patient. We report a case of nodular sclerosis Hodgkin lymphoma which first manifested clinically as Pancoast syndrome and which was initially diagnosed by bronchial biopsy.


Subject(s)
Bronchial Neoplasms/diagnosis , Hodgkin Disease/diagnosis , Pancoast Syndrome/diagnosis , Bronchoscopy , Female , Humans , Middle Aged , Radiography, Thoracic , Tomography, X-Ray Computed
8.
Br J Haematol ; 114(1): 99-103, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11472351

ABSTRACT

Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)-form (50%), eight variable (V)-form (5%) and 76 short (S)-form (45%). The V-form and S-form groups presented a significantly higher percentage of patients with white blood cell counts > 10 x 10(9)/l (P < 0.05). The S-form cases displayed a significantly higher number of cases with M3v microgranular features (P = 0.005) and CD34 expression (P < 0.0001). There were no differences between the three isoforms in complete remission (CR) rate (overall CR 90%), but the 3-year disease-free survival was lower for V-form cases than it was for L- and S-form cases (62% vs. 94% and 89%, P = 0.056). We conclude that the V-form and S-form types are associated with some negative prognostic features at diagnosis. However, our data were only able to demonstrate an association with adverse prognosis in the V-form type and, moreover, as the number of cases was limited, needs to be confirmed in large, uniformly treated series.


Subject(s)
Leukemia, Promyelocytic, Acute/metabolism , Neoplasm Proteins/genetics , Oncogene Proteins, Fusion/genetics , Adolescent , Adult , Aged , Antigens, CD34/analysis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Infant , Infant, Newborn , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/immunology , Leukocyte Count , Male , Middle Aged , Polymerase Chain Reaction/methods , Prognosis , Proportional Hazards Models , Protein Isoforms/genetics , Treatment Outcome , Tretinoin/therapeutic use
9.
Blood ; 94(9): 3015-21, 1999 Nov 01.
Article in English | MEDLINE | ID: mdl-10556184

ABSTRACT

The Spanish PETHEMA group designed a protocol for newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia (APL) in which induction and consolidation followed the original AIDA regimen, except for the omission of cytarabine and etoposide from consolidation. Induction consisted of 45 mg/m(2) all-trans retinoic acid (ATRA) daily until complete remission (CR) and 12 mg/m(2) idarubicin on days 2, 4, 6, and 8. Patients in CR received 3 monthly chemotherapy courses: idarubicin 5 mg/m(2)/d x 4 (course no. 1), mitoxantrone 10 mg/m(2)/d x 5 (course no. 2), and idarubicin 12 mg/m(2)/d x 1 (course no. 3). Maintenance therapy consisted of 90 mg/m(2)/d mercaptopurine orally, 15 mg/m(2)/wk methotrexate intramuscularly, and, intermittently, 45 mg/m(2)/d ATRA for 15 days every 3 months. Between November 1996 and December 1998, 123 patients with newly diagnosed PML/RARalpha-positive APL from 39 centers were enrolled. A total of 109 patients achieved CR (89%; 95% confidence interval [CI], 83 to 95), 12 died of early complications, and the remaining 2 were resistant. Consolidation treatment was associated with very low toxicity and no deaths in remission were recorded. Molecular assessment of response by reverse transcriptase-polymerase chain reaction (RT-PCR) showed conversion to PCR-negative in 48 of 99 (51%) and 82 of 88 patients (93%) after induction and consolidation, respectively. The 2-year Kaplan-Meier estimates of overall survival and event-free survival were 82% +/- 4% and 79% +/- 4%, respectively. For patients who achieved CR, the 2-year disease-free survival (DFS) was 92% +/- 3%. These data indicate that a significant reduction in toxicity might be obtained in APL using a less intensive consolidation without apparently compromising the antileukemic effect. These results also suggest a minor role for cytarabine and etoposide in the treatment of newly diagnosed PML/RARalpha-positive APL patients.


Subject(s)
Anthracyclines/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Leukemia, Promyelocytic, Acute/drug therapy , Neoplasm Proteins , Oncogene Proteins, Fusion , Adolescent , Adult , Aged , Anthracyclines/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Female , Humans , Idarubicin/administration & dosage , Idarubicin/adverse effects , Male , Middle Aged , Treatment Outcome , Tretinoin/administration & dosage , Tretinoin/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...